Advertisement
American Journal of Kidney Diseases

Association of Predicted HLA T-Cell Epitope Targets and T-Cell–Mediated Rejection After Kidney Transplantation

      Rationale & Objective

      The relationship between human leukocyte antigen (HLA) molecular mismatches and T-cell–mediated rejection (TCMR) is unknown. We investigated the associations between the different donor HLA–derived T-cell targets and the occurrence of TCMR and borderline histologic changes suggestive of TCMR after kidney transplantation.

      Study Design

      Retrospective cohort study.

      Setting & Participants

      All kidney transplant recipients at a single center between 2004 and 2013 with available biopsy data and a DNA sample for high-resolution HLA donor/recipient typing (N = 893).

      Exposure

      Scores calculated by the HLA matching algorithm PIRCHE-II and HLA eplet mismatches.

      Outcome

      TCMR, borderline changes suggestive of TCMR, and allograft failure.

      Analytical Approach

      Multivariable cause-specific hazards models were fit to characterize the association between HLA epitopes targets and study outcomes.

      Results

      We found 277 patients developed TCMR, and 134 developed only borderline changes suggestive of TCMR on at least 1 biopsy. In multivariable analyses, only the PIRCHE-II scores for HLA-DRB1 and HLA-DQB1 were independently associated with the occurrence of TCMR and with allograft failure; this was not the case for HLA class I molecules. If restricted to rejection episodes within the first 3 months after transplantation, only the T-cell epitope targets originating from the donor’s HLA-DRB1 and HLA-DQB1, but not class I molecules, were associated with the early acute TCMR. Also, the median PIRCHE-II score for HLA class II was statistically different between the patients with TCMR compared to the patients without TCMR (129 [IQR, 60-240] vs 201 [IQR, 96-298], respectively; P < 0.0001). These differences were not observed for class I PIRCHE-II scores.

      Limitations

      Observational clinical data and residual confounding.

      Conclusions

      In the absence of HLA-DSA, HLA class II but not class I mismatches are associated with early episodes of acute TCMR and allograft failure. This suggests that current immunosuppressive therapies are largely able to abort the most deleterious HLA class I–directed alloimmune processes; however, alloresponses against HLA-DRB1 and HLA-DQB1 molecular mismatches remain insufficiently suppressed.

      Plain-Language Summary

      Genetic differences in the human leukocyte antigen (HLA) complex between kidney transplant donors and recipients play a central role in T-cell–mediated rejection (TCMR), which can lead to failure of the transplanted kidney. Evaluating this genetic disparity (mismatch) in the HLA complex at the molecular (epitope) level could contribute to better prediction of the immune response to the donor organ posttransplantation. We investigated the associations of the different donor HLA–derived T-cell epitope targets and scores obtained from virtual crossmatch algorithms with the occurrence of TCMR, borderline TCMR, and graft failure after kidney transplantation after taking into account the influence of donor-specific anti-HLA antibodies. This study illustrates the greater importance of the molecular mismatches in class II molecules compared to class I HLA molecules.

      Graphical abstract

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dunn T.B.
        • Noreen H.
        • Gillingham K.
        • et al.
        Revisiting traditional risk factors for rejection and graft loss after kidney transplantation.
        Am J Transplant. 2011; 11: 2132-2143https://doi.org/10.1111/j.1600-6143.2011.03640.x
        • Orandi B.J.
        • Chow E.H.K.
        • Hsu A.
        • et al.
        Quantifying renal allograft loss following early antibody-mediated rejection.
        Am J Transplant. 2015; 15: 489-498https://doi.org/10.1111/ajt.12982
        • Cherukuri A.
        • Mehta R.
        • Sharma A.
        • et al.
        Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell–mediated rejection and non-adherence.
        Kidney Int. 2019; 96: 202-213https://doi.org/10.1016/j.kint.2019.01.033
        • Loupy A.
        • Vernerey D.
        • Tinel C.
        • et al.
        Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts.
        J Am Soc Nephrol. 2015; 26: 1721-1731https://doi.org/10.1681/ASN.2014040399
        • Senev A.
        • Coemans M.
        • Lerut E.
        • et al.
        Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: an observational cohort study.
        J Am Soc Nephrol. 2020; 31: 2193-2204https://doi.org/10.1681/ASN.2020010019
        • Filippone E.J.
        • Farber J.L.
        Humoral immune response and allograft function in kidney transplantation.
        Am J Kidney Dis. 2015; 66: 337-347https://doi.org/10.1053/j.ajkd.2015.03.033
        • Opelz G.
        Importance of HLA antigen splits for kidney transplant matching.
        Lancet. 1988; 332: 61-64https://doi.org/10.1016/S0140-6736(88)90001-3
        • Tambur A.R.
        • Claas F.H.J.
        HLA epitopes as viewed by antibodies: what is it all about?.
        Am J Transplant. 2015; 15: 1148-1154https://doi.org/10.1111/ajt.13192
        • Sypek M.
        • Kausman J.
        • Holt S.
        • Hughes P.
        HLA epitope matching in kidney transplantation: an overview for the general nephrologist.
        Am J Kidney Dis. 2018; 71: 720-731https://doi.org/10.1053/j.ajkd.2017.09.021
        • Duquesnoy R.J.
        • Marrari M.
        • Tambur A.R.
        • et al.
        First report on the antibody verification of HLA-DR, HLA-DQ and HLA-DP epitopes recorded in the HLA Epitope Registry.
        Hum Immunol. 2014; 75: 1097-1103https://doi.org/10.1016/j.humimm.2014.09.012
        • Kosmoliaptsis V.
        • Sharples L.D.
        • Chaudhry A.N.
        • Halsall D.J.
        • Bradley J.A.
        • Taylor C.J.
        Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms.
        Transplantation. 2011; 91: 183-190https://doi.org/10.1097/TP.0b013e3181ffff99
        • Kramer C.S.M.
        • Koster J.
        • Haasnoot G.W.
        • Roelen D.L.
        • Claas F.H.J.
        • Heidt S.
        HLA-EMMA: a user-friendly tool to analyse HLA class I and class II compatibility on the amino acid level.
        HLA. 2020; 96: 43-51https://doi.org/10.1111/tan.13883
        • Wiebe C.
        • Kosmoliaptsis V.
        • Pochinco D.
        • et al.
        HLA-DR/DQ molecular mismatch: a prognostic biomarker for primary alloimmunity.
        Am J Transplant. 2019; 19: 1708-1719https://doi.org/10.1111/ajt.15177
        • Tambur A.R.
        HLA-epitope matching or eplet risk stratification: the devil is in the details.
        Front Immunol. 2018; 9: 2010https://doi.org/10.3389/fimmu.2018.02010
        • Kumru Sahin G.
        • Unterrainer C.
        • Süsal C.
        Critical evaluation of a possible role of HLA epitope matching in kidney transplantation.
        Transplant Rev (Orlando). 2020; 24100533https://doi.org/10.1016/j.trre.2020.100533
        • Otten H.G.
        • JJA Calis
        • Keşmir C.
        • van Zuilen A.D.
        • Spierings E.
        Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation.
        Hum Immunol. 2013; 74: 290-296https://doi.org/10.1016/j.humimm.2012.12.004
        • Lachmann N.
        • Niemann M.
        • Reinke P.
        • et al.
        Donor–recipient matching based on predicted indirectly recognizable HLA epitopes independently predicts the incidence of de novo donor-specific HLA antibodies following renal transplantation.
        Am J Transplant. 2017; 17: 3076-3086https://doi.org/10.1111/ajt.14393
        • Bouatou Y.
        • Viglietti D.
        • Pievani D.
        • et al.
        Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell–mediated rejection.
        Am J Transplant. 2019; 19: 1972-1988https://doi.org/10.1111/ajt.15299
        • Senev A.
        • Emonds M.P.
        • Van Sandt V.
        • et al.
        Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation.
        Am J Transplant. 2020; 20: 3367-3378https://doi.org/10.1111/ajt.15938
        • Senev A.
        • Lerut E.
        • Van Sandt V.
        • et al.
        Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.
        Am J Transplant. 2019; 19: 3100-3113https://doi.org/10.1111/ajt.15414
        • Roufosse C.
        • Simmonds N.
        • Clahsen-Van Groningen M.
        • et al.
        2018 reference guide to the Banff classification of renal allograft pathology.
        Transplantation. 2018; 102: 1795-1814https://doi.org/10.1097/TP.0000000000002366
        • Senev A.
        • Coemans M.
        • Lerut E.
        • et al.
        Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome.
        Am J Transplant. 2019; 19: 763-780https://doi.org/10.1111/ajt.15074
        • Loupy A.
        • Haas M.
        • Roufosse C.
        • et al.
        The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell– and antibody-mediated rejection.
        Am J Transplant. 2020; 20: 2318-2331https://doi.org/10.1111/ajt.15898
        • Ali J.M.
        • Bolton E.M.
        • Andrew Bradley J.
        • Pettigrew G.J.
        Allorecognition pathways in transplant rejection and tolerance.
        Transplantation. 2013; 96: 681-688https://doi.org/10.1097/TP.0b013e31829853ce
        • Geneugelijk K.
        • Spierings E.
        Matching donor and recipient based on predicted indirectly recognizable human leucocyte antigen epitopes.
        Int J Immunogenet. 2018; 45: 41-53https://doi.org/10.1111/iji.12359
        • Lim W.H.
        • Wong G.
        • Heidt S.
        • Claas F.H.J.J.
        Novel aspects of epitope matching and practical application in kidney transplantation.
        Kidney Int. 2017; 93: 314-324https://doi.org/10.1016/j.kint.2017.08.008
        • Duquesnoy R.J.
        HLA epitope based matching for transplantation.
        Transplant Immunol. 2014; 31: 1-6https://doi.org/10.1016/j.trim.2014.04.004
        • Dalloul A.H.
        • Chmouzis E.
        • Ngo K.
        • Fung-Leung W.P.
        Adoptively transferred CD4+ lymphocytes from CD8−/− mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts.
        J Immunol. 1996; 156: 4114-4119
        • Meneghini M.
        • Crespo E.
        • Niemann M.
        • et al.
        Donor/recipient HLA molecular mismatch scores predict primary humoral and cellular alloimmunity in kidney transplantation.
        Front Immunol. 2021; 11623276https://doi.org/10.3389/fimmu.2020.623276
        • Sellarés J.
        • De Freitas D.G.
        • Mengel M.
        • et al.
        Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
        Am J Transplant. 2012; 12: 388-399https://doi.org/10.1111/j.1600-6143.2011.03840.x
        • Naesens M.
        • Kuypers D.R.J.
        • De Vusser K.
        • et al.
        Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure.
        Am J Transplant. 2013; 13: 86-99https://doi.org/10.1111/j.1600-6143.2012.04304.x
        • Nankivell B.J.
        • Shingde M.
        • Keung K.L.
        • et al.
        The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: the Banff i-IFTA lesion.
        Am J Transplant. 2018; 18: 364-376https://doi.org/10.1111/ajt.14609
        • Reindl-Schwaighofer R.
        • Heinzel A.
        • Gualdoni G.A.
        • Mesnard L.
        • Claas F.H.J.
        • Oberbauer R.
        Novel insights into non-HLA alloimmunity in kidney transplantation.
        Transplant Int. 2020; 33: 5-17https://doi.org/10.1111/tri.13546
        • Devos J.M.
        • Gaber A.O.
        • Knight R.J.
        • et al.
        Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.
        Kidney Int. 2012; 82: 598-604https://doi.org/10.1038/ki.2012.190
        • Willicombe M.
        • Brookes P.
        • Sergeant R.
        • et al.
        De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy.
        Transplantation. 2012; 94: 172-177https://doi.org/10.1097/TP.0b013e3182543950
        • Sawyer G.J.
        • Dalchau R.
        • Fabre J.W.
        Indirect T cell allorecognition: a cyclosporin A resistant pathway for T cell help for antibody production to donor MHC antigens.
        Transplant Immunol. 1993; 1: 77-81https://doi.org/10.1016/0966-3274(93)90063-E

      Linked Article

      • Molecular Mismatch and the Risk for T Cell–Mediated Rejection
        American Journal of Kidney DiseasesVol. 80Issue 6
        • Preview
          T cell–mediated rejection (TCMR) is evidence of alloimmune reactivity characterized by inflammation within the tubules, interstitial space, and/or arterial intima and media in kidney transplantation. Risk factors for TCMR include younger recipient age, delayed graft function, inadequate immunosuppression, and HLA mismatch.1-6 Advances in genetics and 3-dimensional modeling have led to a renaissance in human leukocyte antigen (HLA) mismatch assessment through the evaluation of such mismatches at the molecular level.
        • Full-Text
        • PDF